Vibecotamab Appears Safe for Low-Blast, High Risk MDS and CMML | Docwire News
In low-blast, high-risk myeloid diseases, including myelodysplastic syndrome and chronic myelomonocytic leukemia, vibecotamab appeared well-tolerated.
In low-blast, high-risk myeloid diseases, including myelodysplastic syndrome and chronic myelomonocytic leukemia, vibecotamab appeared well-tolerated.
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering…
The research group will design a vaccine that won’t promote inflammation.
AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features. Edited by Jennifer…
Research is central to improving outcomes of people diagnosed with and living with lung cancer. In 2025, LUNGevity is proud to continue our commitment to…
Endemic aims squarely at reckoning with comprehending and living with a new respiratory disease and how to face the coming variants. Order your copy today!
Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?
L-Carnitine, sourced from red meat, dairy, and endogenous synthesis, plays a vital role in fatty acid metabolism and energy production. While beneficial for cardiovascular, muscular,…
Len Usvyat spoke with Nephrology Times about the use of artificial intelligence and analytics in kidney care.
Pop stars took advantage of the SVOG grant, using COVID relief funds for luxury spending. Lil Wayne bought Balenciaga and flew private.
The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease.